Novel fluoroimmunoassay for ovarian cancer biomarker CA-125.
Cancer antigen 125 (CA-125) is a glycoprotein biomarker that denotes the presence of ovarian and reproductive cancers in women, with serum concentrations of CA-125 greater than 35 U/ml considered indicative of potential malignancies. A fluorescent immunoassay recently developed in our laboratory employing the ALYGNSA antibody-orientation system has been used to measure CA-125 levels. This system displayed significantly increased sensitivity with a detection limit of 1.5 U/ml compared to that of a commercial CA-125 enzyme-linked immunosorbent assay (15 U/ml) This tenfold lower level of detection of the ALYGNSA CA-125 assay should permit better identification and monitoring of ovarian cancer.
Sok
Davin
D
Biochemistry Program, Department of Chemistry, College of Arts and Sciences, University of Massachusetts, Lowell, MA, 01854, USA.
Clarizia
Lisa-Jo A
LJ
Farris
Leslie R
LR
McDonald
Melisenda J
MJ
D018262:Adenocarcinoma, Clear Cell / Q000175:diagnosis* / Q000276:immunology / Q000517:prevention & control; D018269:Carcinoma, Endometrioid / Q000175:diagnosis* / Q000276:immunology / Q000517:prevention & control; D018284:Cystadenocarcinoma, Serous / Q000175:diagnosis* / Q000276:immunology / Q000517:prevention & control; D005260:Female; D015200:Fluoroimmunoassay; D006801:Humans; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000276:immunology / Q000517:prevention & control; D012680:Sensitivity and Specificity